Contemporary Pediatrics week in review: Updated COVID-19 vaccine approved, FDA-approved biosimilar, and more
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Contemporary Pediatrics week in review | Image Credit: Contemporary Pediatrics
Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from last week (Monday, October 2 to Friday, October 6, 2023) and click on each link to read and watch anything you may have missed.
1.) Updated Novavax COVID-19 vaccine authorized for individuals 12 years and up
Individuals 12 years and older can now receive the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) to protect against variants that are currently circulating, after receiving an Emergency Use Authorization from the FDA.
Click here for the full article.
2.) FDA approves tocilizumab-bavi as biosimilar for PJIA, SJIA in children 2 years and up
Tocilizumab-bavi (Tofidence; Biogen) demonstrated a biosimilarity to tocilizumab (Actemra; Genentech) based on multifaceted clinical and non-clinical data for polyarticular juvenile idiopathic arthritis (PJIA) and systemic juvenile idiopathic arthritis (sJIA) in children aged 2 years and up. This makes it the first tocilizumab biosimilar to be FDA-approved in the United States, according to Biogen.
Click here for the full article.
3.) Nedosiran injection FDA-approved for children with primary hyperoxaluria type 1
The approval of the prescription injection for children aged 9 years and up is based on data from a phase 2 and an ongoing phase 3 trial extension study, that demonstrated the lowering of urinary oxalate levels for individuals with primary hyperoxaluria type 1 (PH1).
Click here for the full article.
4.) FDA issues health care provider letter for probiotics in preterm infants
The FDA has issued a Dear Healthcare Provider Letter highlighting information about the use of probiotics in preterm infants and the risk for potentially fatal disease caused by bacteria or fungi contained in these products.
Click here for the full article.
5.) Toxicity related to THC dose in pediatric edible cannabis ingestions
The degree of toxicity following pediatric ingestion of THC was correlated to the dose of THC, as ingestions of 1.7 mg/kg or more were predictive of severe and prolonged toxicity, according to a study published in Pediatrics.
Click here for the full article.
6.) Facial birthmark and new-onset seizures in infant
The parents of a 3-month-old girl seek medical advice regarding recent seizures and a facial birthmark. What’s the diagnosis?
Lawrence Eichenfield, MD, talks tapinarof cream, 1%, nemolizumab FDA approvals for atopic dermatitis
December 20th 2024"Tapinarof comes in with that mixture of the short-term studies and longer-term studies intermittently, giving us a nice, effective alternative non-steroid for eczema across the ages."
